Status:
COMPLETED
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
Lead Sponsor:
Eli Lilly and Company
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
7-15 years
Phase:
PHASE3
Brief Summary
To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of lif...
Eligibility Criteria
Inclusion
- Diagnosis of ADHD
Exclusion
- Patients who weigh less than 20kg at visit 1
- Have Bipolar Disorder/seizure disorder/taken anticonvulsants for seizures
- Judged to be at suicidal risk
- Taking psychotropic medication on a regular basis
- Hypertension
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00191659
Start Date
June 1 2004
End Date
April 1 2006
Last Update
March 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Basingstoke, Hampshire, United Kingdom, RG24 9NL